Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 342-349

  Gonçalves, Margarida ^a   Tillack, Linda ^b   de Carvalho, Mamede ^c,d   Pinto, Susana ^c,d   Conradt, Harald S ^b   Costa, Júlia ^a  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b GlycoThera GmbH   (Germany)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Cerebrospinal fluid; Glycomics; Glycoproteins; Phosphoneurofilament heavy chain

Indexed keywords

GLYCAN; NEUROFILAMENT PROTEIN; PHOSPHONEUROFILAMENT HEAVY CHAIN; SIALIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FUCOSE; N ACETYLGLUCOSAMINE; NEUROFILAMENT PROTEIN H; PHOSPHOPROTEIN; POLYSACCHARIDE; SIALIC ACID DERIVATIVE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GLYCOBIOLOGY; HUMAN; HYDROLYSIS; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; AGED; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CHEMISTRY; DEVICES; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES;

ACETYLGLUCOSAMINE; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUCOSE; GLYCOMICS; GLYCOSYLATION; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEUROFILAMENT PROTEINS; PHOSPHOPROTEINS; POLYSACCHARIDES; SIALIC ACIDS;

EID: 84908125781     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.09.011     Document Type: Article

References (39)

1. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
2. Chio A., Mora G., Calvo A., Mazzini L., Bottacchi E., Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009, 72:725-731.
3. Valdmanis P.N., Rouleau G.A. Genetics of familial amyotrophic lateral sclerosis. Neurology 2008, 70:144-152.
4. Costa J., Gomes C., de Carvalho M. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2010, 9:764-778.
5. Otto M., Bowser R., Turner M., Berry J., Brettschneider J., Connor J., et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012, 13:1-10.
6. Palma A.S., De Carvalho M., Grammel N., Pinto S., Barata N., Conradt H.S., et al. Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008, 9:339-349.
7. Carilho R., de Carvalho M., Kuehl U., Pinto S., Pinto A., Kromminga A., et al. Erythropoietin and amyotrophic lateral sclerosis: plasma level determination. Amyotroph Lateral Scler 2011, 12:439-443.
8. Carilho R., de Carvalho M., Swash M., Pinto S., Pinto A., Costa J. Vascular endothelial growth factor and amyotrophic lateral sclerosis: the interplay with exercise and non-invasive ventilation. Muscle Nerve 2013, 49:545-550.
9. Lehnert S., Costa J., de Carvalho M., Kirby J., Kuzma-Kozakiewicz M., Morelli C., et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degeneration 2014, 15:344-350.
10. Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66:852-856.
11. Ganesalingam J., An J., Shaw C.E., Shaw G., Lacomis D., Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011, 117:528-537.
12. Boylan K., Yang C., Crook J., Overstreet K., Heckman M., Wang Y., et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009, 111:1182-1191.
13. Toivonen J.M., Manzano R., Olivan S., Zaragoza P., Garcia-Redondo A., Osta R. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One 2014, 9:e89065.
14. Edri-Brami M., Rosental B., Hayoun D., Welt M., Rosen H., Wirguin I., et al. Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells. PLoS One 2012, 7:e35772.
15. May C., Nordhoff E., Casjens S., Turewicz M., Eisenacher M., Gold R., et al. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One 2014, 9:e89596.
16. Prell T., Schenk A., Witte O.W., Grosskreutz J., Gunther A. Transcranial brainstem sonography as a diagnostic tool for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degeneration 2014, 15:244-249.
17. Prell T., Schenk A., Witte O.W., Grosskreutz J., Gunther A. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 2014, 71:442-448.
18. Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., de Carvalho M., et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013, 12:310-322.
19. Ludemann N., Clement A., Hans V.H., Leschik J., Behl C., Brandt R. O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). J Biol Chem 2005, 280:31648-31658.
20. Yuzwa S.A., Shan X., Macauley M.S., Clark T., Skorobogatko Y., Vosseller K., et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 2012, 8:393-399.
21. Jesse S., Lehnert S., Jahn O., Parnetti L., Soininen H., Herukka S.K., et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS One 2012, 7:e48783.
22. Futakawa S., Nara K., Miyajima M., Kuno A., Ito H., Kaji H., et al. A unique N-glycan on human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging 2012, 33:1807-1815.
23. Gonatas N.K., Stieber A., Gonatas J.O. Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. J Neurol Sci 2006, 246:21-30.
24. Gomes C., Palma A.S., Almeida R., Regalla M., McCluskey L.F., Trojanowski J.Q., et al. Establishment of a cell model of ALS disease: Golgi apparatus disruption occurs independently from apoptosis. Biotechnol Lett 2008, 30:603-610.
25. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299.
26. Kandzia S., Costa J. N-glycosylation analysis by HPAEC-PAD and mass spectrometry. Methods Mol Biol 2013, 1049:301-312.
27. Gouveia R., Schaffer L., Papp S., Grammel N., Kandzia S., Head S.R., et al. Expression of glycogenes in differentiating human NT2N neurons. Downregulation of fucosyltransferase 9 leads to decreased Lewis(x) levels and impaired neurite outgrowth. Biochim Biophys Acta 2012, 1820:2007-2019.
28. Bigge J.C., Patel T.P., Bruce J.A., Goulding P.N., Charles S.M., Parekh R.B. Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal Biochem 1995, 230:229-238.
29. Damerell D., Ceroni A., Maass K., Ranzinger R., Dell A., Haslam S.M. The GlycanBuilder and GlycoWorkbench glycoinformatics tools: updates and new developments. Biol Chem 2012, 393:1357-1362.
30. Knezevic A., Gornik O., Polasek O., Pucic M., Redzic I., Novokmet M., et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 2010, 20:959-969.
31. Fogli A., Merle C., Roussel V., Schiffmann R., Ughetto S., Theisen M., et al. CSF N-glycan profiles to investigate biomarkers in brain developmental disorders: application to leukodystrophies related to eIF2B mutations. PLoS One 2012, 7:e42688.
32. Hoffmann A., Nimtz M., Wurster U., Conradt H.S. Carbohydrate structures of beta-trace protein from human cerebrospinal fluid: evidence for ""brain-type"" N-glycosylation. J Neurochem 1994, 63:2185-2196.
33. Hoffmann A., Nimtz M., Getzlaff R., Conradt H.S. Brain-type N-glycosylation of asialo-transferrin from human cerebrospinal fluid. FEBS Lett 1995, 359:164-168.
34. Stanta J.L., Saldova R., Struwe W.B., Byrne J.C., Leweke F.M., Rothermund M., et al. Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res 2010, 9:4476-4489.
35. Thompson E.J. Proteins of the cerebrospinal fluid 2005, Elsevier. 2nd Ed.
36. Barone R., Sturiale L., Palmigiano A., Zappia M., Garozzo D. Glycomics of pediatric and adulthood diseases of the central nervous system. J Proteomics 2012, 75:5123-5139.
37. van Kamp G.J., Mulder K., Kuiper M., Wolters E.C. Changed transferrin sialylation in Parkinson's disease. Clin Chim Acta 1995, 235:159-167.
38. Maguire T.M., Breen K.C. A decrease in neural sialyltransferase activity in Alzheimer's disease. Dementia 1995, 6:185-190.
39. Halim A., Brinkmalm G., Ruetschi U., Westman-Brinkmalm A., Portelius E., Zetterberg H., et al. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci U S A 2011, 108:11848-11853.